Noblejas-López, M.d.M.; Gandullo-Sánchez, L.; Galán-Moya, E.M.; López-Rosa, R.; Tébar-GarcÃa, D.; Nieto-Jiménez, C.; Gómez-Juárez, M.; Burgos, M.; Pandiella, A.; Ocaña, A.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. Int. J. Mol. Sci. 2022, 23, 5476.
https://doi.org/10.3390/ijms23105476
AMA Style
Noblejas-López MdM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-GarcÃa D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences. 2022; 23(10):5476.
https://doi.org/10.3390/ijms23105476
Chicago/Turabian Style
Noblejas-López, MarÃa del Mar, LucÃa Gandullo-Sánchez, Eva M. Galán-Moya, Raquel López-Rosa, David Tébar-GarcÃa, Cristina Nieto-Jiménez, Mónica Gómez-Juárez, Miguel Burgos, Atanasio Pandiella, and Alberto Ocaña.
2022. "Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer" International Journal of Molecular Sciences 23, no. 10: 5476.
https://doi.org/10.3390/ijms23105476
APA Style
Noblejas-López, M. d. M., Gandullo-Sánchez, L., Galán-Moya, E. M., López-Rosa, R., Tébar-GarcÃa, D., Nieto-Jiménez, C., Gómez-Juárez, M., Burgos, M., Pandiella, A., & Ocaña, A.
(2022). Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 23(10), 5476.
https://doi.org/10.3390/ijms23105476